|
Frontiers of Information Technology & Electronic Engineering
ISSN 2095-9184 (print), ISSN 2095-9230 (online)
2024 Vol.25 No.8 P.1134-1144
Event-triggered adaptive tracking control of a class of nonlinear systems with asymmetric time-varying output constraints
Abstract: This article investigates the event-triggered adaptive neural network (NN) tracking control problem with deferred asymmetric time-varying (DATV) output constraints. To deal with the DATV output constraints, an asymmetric time-varying barrier Lyapunov function (ATBLF) is first built to make the stability analysis and the controller construction simpler. Second, an event-triggered adaptive NN tracking controller is constructed by incorporating an error-shifting function, which ensures that the tracking error converges to an arbitrarily small neighborhood of the origin within a predetermined settling time, consequently optimizing the utilization of network resources. It is theoretically proven that all signals in the closed-loop system are semi-globally uniformly ultimately bounded (SGUUB), while the initial value is outside the constraint boundary. Finally, a single-link robotic arm (SLRA) application example is employed to verify the viability of the acquired control algorithm.
Key words: Adaptive control; Deferred asymmetric time-varying output constraints; Error-shifting function; Event-triggered control
1浙江大学医学院附属邵逸夫医院检验科,中国杭州市,310016
2浙江大学医学院附属邵逸夫医院肿瘤内科,中国杭州市,310016
3浙江省医学精准检验与监测研究重点实验室,中国杭州市,310016
4永康市中医院西城分院,中国金华市,321300
摘要:近期研究表明,血管内皮生长因子受体抑制剂(VEGFRi)可以增强程序性死亡受体1(PD-1)抗体对微卫星稳定(MSS)结直肠癌(CRC)的抗肿瘤活性。然而,与标准三线VEGFRi治疗相比,这种联合治疗的疗效尚未明确,且目前缺乏可靠的生物标志物。本研究中,我们回顾性纳入了接受PD-1抗体联合VEGFRi(联合组,n=54)或单独VEGFRi(VEGFRi组,n=32)治疗的MSS CRC患者,并评估了其疗效和安全性。我们通过单细胞和空间转录组数据进一步研究了MSS CRC肿瘤微环境(TME)的免疫特征,构建了一个预测接受免疫治疗的MSS CRC患者临床结局的MSS CRC免疫细胞相关特征(MCICRS),并在内部队列中对其进行验证。研究发现,与单独VEGFRi治疗相比,PD-1抗体联合VEGFRi治疗能显著延长患者的生存期(中位无进展生存期:4.4个月 vs. 2.0个月,P=0.0024;中位总生存期:10.2个月 vs. 5.2个月,P=0.0038),且两组间不良事件的发生率相当。进一步通过单细胞和空间转录组分析,我们确定了10种MSS CRC富集的免疫细胞类型及其空间分布,包括幼稚CD4+ T细胞、调节性CD4+ T细胞、CD4+ Th17细胞、耗竭CD8+ T细胞、细胞毒性CD8+ T细胞、增殖CD8+ T细胞、自然杀伤(NK)细胞、浆细胞和经典/中间型单核细胞。基于meta分析和10种机器学习算法,我们构建了MCICRS,其是一个独立的MSS CRC患者的预后风险因素。通过进一步分析,MCICRS低风险组患者表现出更高的免疫细胞浸润和免疫相关通路激活,同时与泛癌免疫治疗的客观反应率和无进展生存有显著关联。最后,MCICRS在MSS CRC接受免疫治疗的预测价值也在内部队列中得到了验证。综上所述,PD-1抗体联合VEGFRi可以改善MSS CRC的临床结局且可控制毒性,同时MCICRS可以作为一个强大且有前景的工具,用于预测接受免疫治疗的MSS CRC患者的临床结局。
关键词组:
References:
Open peer comments: Debate/Discuss/Question/Opinion
<1>
DOI:
10.1631/FITEE.2300679
CLC number:
TP273
Download Full Text:
Downloaded:
955
Download summary:
<Click Here>Downloaded:
277Clicked:
1558
Cited:
0
On-line Access:
2024-08-27
Received:
2023-10-17
Revision Accepted:
2024-05-08
Crosschecked:
2024-03-03